Skin News and Research

RSS

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Intendis GmbH forges agreement with SkinMedica to acquire two prescription dermatology products

Asset Purchase Agreement Signed for Marketed Prescription Products Desonate(R) and NeoBenz(R) Micro

3 Sep 2009

Alloantigen-specific Treg cells targeted for organ transplantation

An increased understanding of the role of the body's immune system in the development of diseases such as prostate cancer, squamous cell carcinoma (a type of skin cancer), type 1 diabetes, autoimmune liver disease, and in the rejection of transplanted organs by some transplant patients, has paved the way for a pioneering research programme which aims to develop 'enhanced' cells as therapies.

3 Sep 2009

New therapy for advanced and metastatic basal cell skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

Scientists demonstrate the link between cancer and diesel fumes

Scientists here are the first to demonstrate that the link between diesel fume exposure and cancer lies in the ability of diesel exhaust to induce the growth of new blood vessels that serve as a food supply for solid tumors.

2 Sep 2009

Cavit Sciences and McCoy form an agreement to finalize their merger

Cavit management has been negotiating with Randall McCoy and Joe Connell principle owners of McCoy Enterprises LLC to merge our companies. Maggie Smyth, CEO of Cavit states, “We all feel very good about this fit so we have added a breakup clause to show our commitment to each other”.

2 Sep 2009

Hope for limiting skin toxicity of cancer drug users

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

Ground breaking surgery leaves no unsightly scar

Surgeons at The Montreal Children's Hospital of the McGill University Health Centre and McGill University used a novel approach for the first time in Canada to remove a tumour embedded in the upper face of Jayden Cambridge, an 18-month old child.

2 Sep 2009

Biotransformed blueberry juice can function as anti-obesity and anti-diabetic agent

Juice extracted from North American lowbush blueberries, biotransformed with bacteria from the skin of the fruit, holds great promise as an anti-obesity and anti-diabetic agent. The study, published in the International Journal of Obesity, was conducted by researchers from the Universit- de Montr-al, the Institut Armand-Frappier and the Universit- de Moncton who tested the effects of biotransformed juices compared to regular blueberry drinks on mice.

2 Sep 2009

MammoSite ML radiation therapy system approved for breast cancer treatment

Hologic, Inc. (Hologic or the Company), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the U.S. Food and Drug Administration (FDA) cleared the Company's 510K application for the MammoSite((R)) ML radiation therapy system.

1 Sep 2009

AAD urges Americans to remind grandparents to perform skin self-examination

Sunday, September 13, is National Grandparents Day, and the American Academy of Dermatology (Academy) recommends that people lovingly remind their grandparents to perform a skin self-examination.

1 Sep 2009

TransPharma's Phase 2A trial of ViaDerm-hPTH(1-34) for treating severe osteoporosis is successful

TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug products utilizing a proprietary active transdermal drug delivery technology, announced today the successful completion of the Phase 2A trial of ViaDerm-hPTH(1-34) which is being developed for the treatment of severe osteoporosis.

1 Sep 2009

Study provides insights into genes that help maintain youthfulness of the skin

In the new print issue of Nature Genetics, scientists in Singapore and Germany report that mutations in the PYCR1 gene cause the rare genetic condition that results in premature skin aging and that is known as "wrinkly skin syndrome."

1 Sep 2009

OHSU study reveals that fluoroquinolones may cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

1 Sep 2009

MabCure featured in the August edition of Biotechnology Focus magazine

MabCure, Inc. (“MabCure”), a biotechnology company using its proprietary technology to create highly specific monoclonal antibodies (MAbs) for the early detection of cancer, has been featured in the August edition of Biotechnology Focus, Canada's oldest and most successful magazine serving the Canadian life science industry.

31 Aug 2009

Two senior members of Chertoff Group to provide operational advisory services to BioNeutral Group

BioNeutral Group, Inc. has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company’s strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.

31 Aug 2009

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.

31 Aug 2009